Skip to main content

Postdoc Portrait: Pooja Mittal Investigates Molecular Biomarkers in Colorectal Cancer

This postdoctoral researcher explores biomarkers and the tumor microenvironment. She hopes to develop therapeutic strategies to combat colorectal cancer.

Brought to you byThe Scientist
| 2 min read
Headshot of postdoctoral researcher Pooja Mittal.
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Pooja Mittal is a postdoctoral researcher at the University of Southern California Keck School of Medicine. In this Postdoc Portrait, she discusses how her work focuses on finding new and effective treatment strategies for colorectal cancer.

Colorectal Cancer Therapies and Tumor Microenvironment

Q | What drew you to studying colorectal cancer?

Colorectal cancer is one of the most common causes of cancer-related mortality worldwide and thus it is a very important research field. The major target that drew me towards this field was myeloid cell leukemia-1 (MCL-1) which is a protein that helps the cancer cells to avoid cell death.

Q | What scientific problem are you trying to solve?

I am currently working to identify and analyze different biomarkers in colorectal cancer. Another domain of my research includes identifying new treatments against these biomarkers. The biomarkers and associated therapies will subsequently result in better diagnosis, treatment and prognosis of colorectal cancer.

Q | What’s one thing you learned from your research that you didn’t expect?

When I started I was more focused on the role of protein MCL-1 in cancer cells, however, while working on this research project I got a broader perspective of its involvement not only in cancer cells but also the tumor microenvironment, which I had not envisioned earlier.

Q | If your research succeeds, what could it change for science or society?

My research is primarily focused on finding new and effective treatment strategies for colorectal cancer. Colorectal cancer is a leading cause of cancer-related mortality worldwide and its incidence is recently increasing in young patients aged less than 50 years, so finding treatments which can benefit the therapeutic outcome and survival in these patients is very crucial.

Q | What question are you most excited to answer next?

Nuclear genome has been widely studied in cancer, however recently mitochondrial genome or mitochondrial DNA (mtDNA) is emerging as a potential biomarker in various cancers. My next project would be to see how the modulation in mtDNA can affect colorectal cancer.

Responses have been edited for length and clarity.

Are you a researcher who would like to be featured in the “Postdoc Portraits” series? Send in your application here.

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
The Scientist October Digest cover
October 2026

Antarctica’s Blood Falls Teems With Mysterious Microbial Life

Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.

View this Issue
Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

​Beckman Coulter
Find better biologics faster with Stunner and the AI Developability Workcell

Find better biologics faster with Stunner and the AI Developability Workcell

Unchained Labs
An image of microcentrifuge tubes arranged within colorful laboratory racks.

Choose clarity. Choose speed. Choose MyMass™

Refeyn
Characterizing LNP Heterogeneity With Super-Resolution Imaging

Characterizing LNP Heterogeneity With Super-Resolution Imaging

Oni

Products

Stellaromics Logo

Stellaromics Expands Pyxa Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and EuropeStellaromics, Inc., the leader in 3D

A monoclonal antibody surrounded by immune cells and red blood cells

CellRaft AIR: Find the Right Antibody-Producing Cells Faster

Cell Microsystems
Maxwell® Rapid ccfDNA Kit

Maxwell® Rapid ccfDNA Kit: Automated Purification of ccfDNA in Under 30 Minutes

Promega
Leica Biosystems, Tempus, and Paige logos side by side, marking the addition of Paige digital pathology AI tools to the Aperio AI Store.

Oncology Researchers Gain AI Cancer Tools in One Platform